4572 — Carna Biosciences Share Price
0.000.00%
Last trade - 00:00- ¥5bn
- ¥3bn
- ¥636m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.07 | ||
| Price to Tang. Book | 2.07 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.04 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -85.1% | ||
| Return on Equity | -68.59% | ||
| Operating Margin | -340.97% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 1,133.35 | 2,017.53 | 1,386.75 | 1,625.89 | 636.24 | n/a | n/a | -27.64% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Carna Biosciences, Inc. is a Japan-based company mainly engaged in the drug development support business and the drug development business. The Company operates in two business segments. The Drug Development Support segment is engaged in sales of protein kinase, development of assay, as well as provision of profiling and screening service. The Drug Development segment is engaged in the research and development of kinase inhibitors and other drugs.
Directors
- Koichiro Yoshino PRE (72)
- Shinichi Kuwahara EDR (64)
- Norio Aikawa OTH (68)
- Masaaki Sawa OTH
- Eimi Yamamoto OTH
- Teruo Takayanagi IND
- Tsunehisa Yanagihara IND (74)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 10th, 2003
- Public Since
- March 25th, 2008
- No. of Shareholders
- 9,559
- No. of Employees
- 63
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 19,096,376
- Address
- KIBC Bldg. 511, KOBE-SHI, 650-0047
- Web
- https://www.carnabio.com/
- Phone
- +81 783027039
- Auditors
- Deloitte Touche Tohmatsu LLC
Upcoming Events for 4572
Dividend For 4572.T - 0.0000 JPY
Similar to 4572
3-D Matrix
Tokyo Stock Exchange
AnGes
Tokyo Stock Exchange
BrightPath Biotherapeutics Co
Tokyo Stock Exchange
Chiome Bioscience
Tokyo Stock Exchange
Chordia Therapeutics
Tokyo Stock Exchange
FAQ
What is the Carna Biosciences share price?
As of Today at 19:47 UTC, shares in Carna Biosciences are trading at ¥268. This share price information is delayed by 15 minutes.
How has the Carna Biosciences share price performed this year?
Shares in Carna Biosciences last closed at ¥268 and the price had moved by -38.81% over the past 365 days. In terms of relative price strength the Carna Biosciences share price has underperformed the Nikkei 225 Index by -35.52% over the past year.
What are the analyst and broker recommendations for Carna Biosciences?
The overall consensus recommendation for Carna Biosciences is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Carna Biosciences dividend yield?
Carna Biosciences does not currently pay a dividend.
Does Carna Biosciences pay a dividend?
Carna Biosciences does not currently pay a dividend.
When does Carna Biosciences next pay dividends?
Carna Biosciences does not currently pay a dividend.
How do I buy Carna Biosciences shares?
To buy shares in Carna Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Carna Biosciences?
As of the previous close price of ¥268, shares in Carna Biosciences had a market capitalisation of ¥5bn.
Where are Carna Biosciences shares listed?
Here are the trading details for Carna Biosciences:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4572
What kind of share is Carna Biosciences?
Based on an overall assessment of its quality, value and momentum Carna Biosciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Carna Biosciences share price forecast for 2025?
The analyst consensus target price for shares in Carna Biosciences is ¥3,400. That is 1168.66% above the last closing price of ¥268.
Analysts covering Carna Biosciences currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Carna Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Carna Biosciences. Over the past six months, its share price has underperformed the Nikkei 225 Index by -6.53%.
As of the last closing price of ¥268, shares in Carna Biosciences were trading -18.13% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Carna Biosciences PE Ratio?
The Carna Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥268.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Carna Biosciences?
Carna Biosciences' management team is headed by:
- Koichiro Yoshino - PRE
- Shinichi Kuwahara - EDR
- Norio Aikawa - OTH
- Masaaki Sawa - OTH
- Eimi Yamamoto - OTH
- Teruo Takayanagi - IND
- Tsunehisa Yanagihara - IND